Clinical Trials
25 trialsNCT06257264 2026-06-05
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06003231 2026-06-01
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
Phase 2 Active not recruiting
NCT04956640 2026-05-29
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05277051 2026-05-22
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT05462717 2026-05-15
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Active not recruiting
NCT04152499 2026-05-11
MK-2870-001
Klus Pharma Inc.
Phase 1/2 Active not recruiting
NCT05520099 2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05858736 2026-04-09
PRESERVE-009
OncoC4, Inc.
Phase 1 Active not recruiting
NCT04044859 2026-04-07
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT03860272 2026-03-30
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
NCT04258813 2026-02-20
ONE TEAM
Duke University
Phase NA Active not recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03983954 2025-11-28
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Phase 1 Active not recruiting
NCT06714617 2025-11-04
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune Inc.
Phase 1 Active not recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03170960 2025-08-17
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Active not recruiting
NCT05057013 2025-08-11
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Phase 1/2 Active not recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04706962 2025-04-15
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
Phase 1 Active not recruiting
NCT03212404 2025-02-03
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05572684 2024-12-16
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Active not recruiting
NCT05931445 2024-04-23
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
Comprehensive Support Project for Oncology Research
Phase NA Active not recruiting